STIM
Neuronetics, Inc.1.6500
-0.1100-6.25%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
113.00MP/E (TTM)
-Basic EPS (TTM)
-0.83Dividend Yield
0%Recent Filings
10-K
8-K
8-K
Amends Madryn registration rights
Neuronetics executed a Second Amendment to its Registration Rights Agreement with Madryn parties on March 2, 2026, tied to the prior Greenbrook TMS arrangement. It mandates filing a resale registration statement for Madryn's shares within five business days post-10-K for 2025. Madryn commits to vote its shares with the board at the 2026 annual meeting on director reelection, auditor ratification, exec comp, and a new equity plan. Locks in support, yet ties liquidity to filings.
8-K
Execs get incentive payouts
Neuronetics approved annual cash incentive awards on February 23, 2026, for key executives: CEO Keith J. Sullivan at $412,775.95, EVP/Chief Legal Officer W. Andrew Macan at $163,383.75, and EVP/CFO Steven E. Pfanstiel at $73,216.44, payable around March 13. Awards reflect Compensation Committee and Board action. Retention tool deployed.
8-K
Q4 revenue surges 86%
Neuronetics reported preliminary Q4 2025 revenue of $41.8M, up 86% year-over-year as reported and 23% on adjusted pro forma basis, driven by $18.3M NeuroStar and $23.5M clinic sales. Full-year revenue hit $149.2M, with positive Q4 operating cash flow of $0.9M. Cash stands at $34.1M. Full results due March 17.
IPO
Employees
Sector
Industry
BWAY
Brainsway Ltd.
16.87-0.47
CLPT
ClearPoint Neuro Inc.
13.82+1.44
CVRX
CVRx, Inc.
8.32+0.14
EMED
Electromedical Technologies, In
0.00+0.00
INSP
Inspire Medical Systems, Inc.
115.51-3.75
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
NRXS
Neuraxis, Inc.
2.70+0.05
NXL
Nexalin Technology, Inc.
0.81-0.01
STME
Stimcell Energetics, Inc.
0.37-0.04